Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Summary: Background: While rifaximin was able to improve symptoms in patients with irritable bowel syndrome (IBS) in phase III trials, these results are yet to be repeated in phase IV studies. Aim: To evaluate the treatment response to rifaximin in IBS patients in a phase IV trial. Methods: IBS patients underwent lactulose hydrogen breath testing (LHBT). LHBT‐positive patients were treated with rifaximin for 14 days. Prior to treatment as well as at week 4 and 14 following the start of rifaximin treatment, patients completed a questionnaire assessing symptom severity on a Likert scale from 0 to 10. Results: One hundred and six of 150 IBS patients (71%) were LHBT‐positive and treated with rifaximin. As assessed at week 4 following commencement of the therapy, rifaximin provided significant improvement of the following IBS‐associated symptoms: bloating (5.5±2.6 before the start of the treatment vs. 3.6±2.7 at week 4, P<0.001), flatulence (5.0±2.7 vs. 4.0±2.7, P=0.015), diarrhoea (2.9±2.4 vs. 2.0±2.4, P=0.005) and abdominal pain (4.8±2.7 vs. 3.3±2.5, P<0.001). Overall well‐being also significantly improved (3.9 ± 2.4 vs. 2.7 ± 2.3, P < 0.001). Similar improvements in IBS symptoms were obtained at week 14. Eighty‐six per cent of patients undergoing repetitive LHBT (55/64) tested negative at week 4. Conclusions: We found a high percentage of LHBT‐positive IBS patients. IBS‐associated symptoms (bloating, flatulence, diarrhoea, pain) were improved for a period of 3 months following 2 weeks of treatment with rifaximin. We conclude that rifaximin treatment alleviates symptoms in LHBT‐positive IBS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 2×
“published phase III, double-blind, placebo-controlled TARGET trials.(17) In these trials, IBS patients without constipation were assigned either to a group that received rifaximin (at a dose of 550 mg) or to a group that received placebo three times daily for 2 weeks.”
MethodResultKassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Ford, A. C., Talley, N. J., Spiegel, B. M. R., Foxx-Orenstein, A. E., Schiller, L., Quigley, E. M. M., & Moayyedi, P. (2008) · BMJ · doi:10.1136/bmj.a2313 · Cited by 565
Pimentel, M., Lin, H. C., Enayati, P., van den Burg, B., Lee, H.-R., Chen, J. H., Park, S., Kong, Y., & Conklin, J. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00574.2004 · Cited by 508
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Ford, A. C., Spiegel, B. M. R., Talley, N. J., & Moayyedi, P. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.031 · Cited by 351 · cited 8×
“95), depending on the criteria used for defining a positive readout of a test.(8) The LHBT is one of the most commonly used breath tests that is based on measurement of hydrogen concentration in breath samples every 15 min (for up to 3 h)”
BackgroundMethodResultInfluentialIncreased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy
Lombardo, L., Foti, M., Ruggia, O., & Chiecchio, A. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.12.022 · Cited by 350
Sharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344 · cited 1×
“70).(20) A recently published meta-analysis on the efficacy and safety of rifaximin in treatment of IBS revealed that rifaximin is, indeed, more efficacious than placebo for global IBS symptom improvement [OR = 1.”
BackgroundA Systematic Review of Diagnostic Tests for Small Intestinal Bacterial Overgrowth
Khoshini, R., Dai, S.-C., Lezcano, S., & Pimentel, M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0065-1 · Cited by 323 · cited 2×
“following the ingestion of 10 g of the non-absorbable sugar lactulose dissolved in water.(9) According to the original definition of the positive LHBT, the rise of >20 ppm in hydrogen concentration occurring at least 15 min before a second rise in hydrogen concentration is”
MethodResultInfluentialYu, D., Cheeseman, F., & Vanner, S. (2011) · Gut · doi:10.1136/gut.2009.205476 · Cited by 284
Menees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283 · cited 2×
“tently been shown to be associated with a very low rate of side effects, which can be explained by the minimal systemic absorption of this antibiotic.(18) Therefore, in our opinion, the use of rifaximin for management of IBS”
BackgroundResult
Cited by
Chong, P. P., Chin, V. K., Looi, C. Y., Wong, W. F., Madhavan, P., & Yong, V. C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01136 · Cited by 328
Gatta, L., & Scarpignato, C. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13928 · Cited by 266
DuPont, H. L. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12728 · Cited by 171
“experienced reduction in bloating, flatulence, diarrhoea and pain) after 2 weeks, and results were maintained for at least 3 months.(60) In addition, several retrospective chart reviews of rifaximin treatment for IBS suggest a low potential for loss of efficacy with repeated courses of rifaximin.”
BackgroundChen, B., Kim, J. J.-W., Zhang, Y., Du, L., & Dai, N. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1476-9 · Cited by 117
Schoenfeld, P., Pimentel, M., Chang, L., Lembo, A., Chey, W. D., Yu, J., Paterson, C., Bortey, E., & Forbes, W. P. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12735 · Cited by 106
Metadata
- Authors
- Meyrat, P., Safroneeva, E., & Schoepfer, A. M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2012-11-16
- Volume
- 36
- Issue
- 11-12
- Pages
- 1084-1093
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2078752617
- Cited by
- 59
- References
- 12
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.